NCT02057406

Omega 3 for Treatment of Depression in Patients With Heart Failure

Omega 3 for Comorbid Depression and Heart Failure Treatment

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 108 (actual)
• Sponsor: Wei Jiang · Academic / Other
• Sex: All
• Age: 21 Years
• Healthy volunteers: Not accepted

Summary

Omega 3 supplements will improve depressive symptoms to a greater extent than placebo in heart failure patients with moderate to severe major depressive disorder.

Detailed description

The primary objective of this study is to determine whether (Hypothesis 1a) and how (Hypothesis 1b) the two omega 3 supplements will reduce depressive symptoms in heart failure (HF) patients with moderate-to-severe major depressive disorder (MDD). Hypothesis 1a: Omega 3 supplements will improve depressive symptoms to a greater extent than placebo; Hypothesis 1b: Pure eicosapentaenoic acid (EPA) will be superior to the EPA: docosahexaenoic acid (DHA) 2:1 in depression improvement.

Conditions

• Depression

Interventions

Type	Name	Description
DRUG	2:1 EPA/DHA	400 Eicosapentaenoic acid/200 docosahexaenoic acid fish oil 2 grams
DRUG	High EPA
OTHER	Placebo

Timeline

• Start date: 2014-05-01
• Primary completion: 2016-05-19
• Completion: 2016-12-02
• First posted: 2014-02-07
• Last updated: 2018-05-14
• Results posted: 2017-06-12

Locations

3 sites across 1 country: United States